Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR Inhibitors

被引:26
|
作者
Lu, Yipin [1 ]
Knapp, Mark [1 ]
Crawford, Kenneth [2 ]
Warne, Robert [2 ]
Elling, Robert [1 ]
Yan, Kelly [2 ]
Doyle, Michael [2 ]
Pardee, Gwynn [2 ]
Zhang, Li [2 ]
Ma, Sylvia [2 ]
Mamo, Mulugeta [1 ]
Ornelas, Elizabeth [1 ]
Pan, Yue [1 ]
Bussiere, Dirksen [1 ]
Jansen, Johanna [1 ]
Zaror, Isabel [2 ]
Lai, Albert [2 ]
Barsanti, Paul [1 ]
Sim, Janet [2 ]
机构
[1] Novartis Inst Biomed Res, Global Discovery Chem, Emeryville, CA 94608 USA
[2] Novartis Inst Biomed Res, Oncol, Emeryville, CA 94608 USA
关键词
ATR; PI3K alpha; mutant; crystal structure; ATR inhibitor; PROTEIN-KINASE-A; CELL-CYCLE; CANCER-CELLS; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; DISCOVERY; POTENT; THERAPY; IDENTIFICATION; DETERMINANTS;
D O I
10.1016/j.jmb.2017.04.006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
ATR, a protein kinase in the PIKK family, plays a critical role in the cell DNA-damage response and is an attractive anticancer drug target. Several potent and selective inhibitors of ATR have been reported showing significant antitumor efficacy, with most advanced ones entering clinical trials. However, due to the absence of an experimental ATR structure, the determinants contributing to ATR inhibitors' potency and specificity are not well understood. Here we present the mutations in the ATP-binding site of PI3K alpha to progressively transform the pocket to mimic that of ATR. The generated PI3K alpha mutants exhibit significantly improved affinity for selective ATR inhibitors in multiple chemical classes. Furthermore, we obtained the X-ray structures of the PI3K alpha mutants in complex with the ATR inhibitors. The crystal structures together with the analysis on the inhibitor affinity profile elucidate the roles of individual amino acid residues in the binding of ATR inhibitors, offering key insights for the binding mechanism and revealing the structure features important for the specificity of ATR inhibitors. The ability to obtain structural and binding data for these PI3K alpha mutants, together with their ATR-like inhibitor binding profiles, makes these chimeric PI3K alpha proteins valuable model systems for structure-based inhibitor design. (C) 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecomnnons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:1684 / 1704
页数:21
相关论文
共 43 条
  • [31] 7-Ketocholesterol induces ATM/ATR, Chk1/Chk2, PI3K/Akt signalings, cytotoxicity and IL-8 production in endothelial cells
    Chang, Mei-Chi
    Chen, Yi-Jane
    Liou, Eric Jein-Wein
    Tseng, Wan-Yu
    Chan, Chiu-Po
    Lin, Hseuh-Jen
    Liao, Wan-Chuen
    Chang, Ya-Ching
    Jeng, Po-Yuan
    Jeng, Jiiang-Huei
    ONCOTARGET, 2016, 7 (46) : 74473 - 74483
  • [32] Evaluation of WO2013117503 and WO2013117504: the use of PI3K inhibitors to treat cough or idiopathic pulmonary fibrosis
    Norman, Peter
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2014, 24 (06) : 719 - 722
  • [33] Exploring the selectivity of PI3Kα and mTOR inhibitors by 3D-QSAR, molecular dynamics simulations and MM/GBSA binding free energy decomposition
    Wu, Feng
    Hou, Xueyan
    Luo, Hao
    Zhou, Meng
    Zhang, Wenjuan
    Ding, Zhenyu
    Li, Rui
    MEDCHEMCOMM, 2013, 4 (11) : 1482 - 1496
  • [34] Discovery and design of new PI3K inhibitors through pharmacophore-based virtual screening, molecular docking, and binding free energy analysis
    Peddi, Saikiran Reddy
    Sivan, Sree Kanth
    Manga, Vijjulatha
    STRUCTURAL CHEMISTRY, 2018, 29 (06) : 1753 - 1766
  • [35] Discovery and design of new PI3K inhibitors through pharmacophore-based virtual screening, molecular docking, and binding free energy analysis
    Saikiran Reddy Peddi
    Sree Kanth Sivan
    Vijjulatha Manga
    Structural Chemistry, 2018, 29 : 1753 - 1766
  • [36] Effective use of PI3K/MTOR and MEK inhibitors prior to hormone ablative therapy in PTEN-loss driven murine prostate cancer
    Patnaik, Akash
    Courtney, Kevin
    Robichaud, Kyle
    Bellinger, Gary
    Nardella, Caterina
    Signoretti, Sabina
    Wooster, Richard
    Pandolfi, Pier Paolo
    Cantley, Lewis
    CANCER RESEARCH, 2012, 72
  • [37] Responsiveness to PI3K and MEK Inhibitors in Breast Cancer. Use of a 3D Culture System to Study Pathways Related to Hormone Independence in Mice
    Laura Polo, Maria
    Victoria Arnoni, Maria
    Riggio, Marina
    Wargon, Victoria
    Lanari, Claudia
    Novaro, Virginia
    PLOS ONE, 2010, 5 (05):
  • [38] Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive (HR plus ) metastatic breast cancer
    Shen, Sherry
    Safonov, Anton
    Bromberg, Maria
    Chen, Yuan
    Ahmed, Mehnaj
    Razavi, Pedram
    Jhaveri, Komal L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia
    Zhang, Kehui
    Huang, Rui
    Ji, Ming
    Lin, Songwen
    Lai, Fangfang
    Wu, Deyu
    Tian, Hua
    Bi, Jinhui
    Peng, Shouguo
    Hu, Jiaqi
    Sheng, Li
    Li, Yan
    Chen, Xiaoguang
    Xu, Heng
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 264
  • [40] Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
    Jeffrey A Engelman
    Liang Chen
    Xiaohong Tan
    Katherine Crosby
    Alexander R Guimaraes
    Rabi Upadhyay
    Michel Maira
    Kate McNamara
    Samanthi A Perera
    Youngchul Song
    Lucian R Chirieac
    Ramneet Kaur
    Angela Lightbown
    Jessica Simendinger
    Timothy Li
    Robert F Padera
    Carlos García-Echeverría
    Ralph Weissleder
    Umar Mahmood
    Lewis C Cantley
    Kwok-Kin Wong
    Nature Medicine, 2008, 14 : 1351 - 1356